Compare GKOS & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | IRTC |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.8B |
| IPO Year | 2015 | 2016 |
| Metric | GKOS | IRTC |
|---|---|---|
| Price | $113.41 | $179.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $127.71 | ★ $207.14 |
| AVG Volume (30 Days) | ★ 641.9K | 383.8K |
| Earning Date | 02-19-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $469,820,000.00 | ★ $702,573,000.00 |
| Revenue This Year | $31.15 | $27.20 |
| Revenue Next Year | $24.15 | $16.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.38 | 25.45 |
| 52 Week Low | $73.16 | $86.99 |
| 52 Week High | $163.71 | $212.00 |
| Indicator | GKOS | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 58.14 | 52.27 |
| Support Level | $109.07 | $173.46 |
| Resistance Level | $115.00 | $191.40 |
| Average True Range (ATR) | 2.76 | 5.20 |
| MACD | -0.95 | 1.12 |
| Stochastic Oscillator | 44.01 | 51.63 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.